Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alnylam Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.8%. By the end of trading, Alnylam Pharmaceuticals fell $0.71 (-1.1%) to $65.73 on average volume. Throughout the day, 669,569 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 779,400 shares. The stock ranged in price between $64.74-$67.97 after having opened the day at $67.15 as compared to the previous trading day's close of $66.44. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 41.3%,




), down 24.8%,

Delcath Systems



TheStreet Recommends

), down 6.5% and

CytRx Corporation



), down 6.2%.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Alnylam Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 264.1% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Alnylam Pharmaceuticals

as a


. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front,




), up 33.7%,

United Therapeutics Corporation



), up 30.4%,

Can Fite Biofarma Ltd. ADR



), up 17.5% and

Celator Pharmaceuticals



), up 16.3% , were all gainers within the drugs industry with

Endo Health Solutions



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.